---
title: "This LSD-Based Drug Just Scored Again. Definium Stock Soars."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295674953.md"
description: "Definium Therapeutics recently announced the successful completion of the second out of two favorable Phase 3 trials for its LSD-derived medication. Following this news, the biotech company's stock saw a significant increase in value. This achievement marks a significant turning point for the company and has generated positive attention from investors."
datetime: "2026-08-12T13:33:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295674953.md)
  - [en](https://longbridge.com/en/news/295674953.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295674953.md)
generator: "portal-rs"
---

# This LSD-Based Drug Just Scored Again. Definium Stock Soars.

Definium Therapeutics recently announced the successful completion of the second out of two favorable Phase 3 trials for its LSD-derived medication. Following this news, the biotech company's stock saw a significant increase in value. This achievement marks a significant turning point for the company and has generated positive attention from investors.

### Related Stocks

- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)

## Related News & Research

- [Definium Therapeutics (DFTX) Stock Looks Fully Valued On Fresh Phase 3 Trial News](https://longbridge.com/en/news/298973753.md)
- [DFTX: DT120 ODT 100 µg met all efficacy endpoints in Phase 3 GAD study, supporting NDA plans](https://longbridge.com/en/news/298907975.md)
- [Definium Therapeutics Announces New Employee Inducement Grants | DFTX Stock News](https://longbridge.com/en/news/298901875.md)
- [Definium Therapeutics to Participate at Upcoming Investor Conferences and Events | DFTX Stock News](https://longbridge.com/en/news/297036608.md)
- [What Do Definium Therapeutics (DFTX) Phase 3 GAD Results Mean For DT120?](https://longbridge.com/en/news/295821556.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**